Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Payables (2020 - 2025)

Bolt Biotherapeutics' Payables history spans 6 years, with the latest figure at $1.5 million for Q3 2025.

  • For Q3 2025, Payables rose 2.43% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, up 2.43%, while the annual FY2024 figure was $1.5 million, 49.55% down from the prior year.
  • Payables for Q3 2025 was $1.5 million at Bolt Biotherapeutics, down from $1.9 million in the prior quarter.
  • Across five years, Payables topped out at $5.2 million in Q3 2021 and bottomed at $1.5 million in Q3 2024.
  • The 5-year median for Payables is $2.9 million (2021), against an average of $2.8 million.
  • The largest annual shift saw Payables soared 123.65% in 2021 before it crashed 59.75% in 2024.
  • A 5-year view of Payables shows it stood at $3.6 million in 2021, then rose by 0.56% to $3.6 million in 2022, then dropped by 16.89% to $3.0 million in 2023, then crashed by 49.55% to $1.5 million in 2024, then grew by 0.73% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Payables are $1.5 million (Q3 2025), $1.9 million (Q2 2025), and $1.5 million (Q1 2025).